335 related articles for article (PubMed ID: 28144708)
1. Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT
McLaughlin PJ; Jagielo-Miller JE; Plyler ES; Schutte KK; Vemuri VK; Makriyannis A
Psychopharmacology (Berl); 2017 Mar; 234(6):1029-1043. PubMed ID: 28144708
[TBL] [Abstract][Full Text] [Related]
2. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
3. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effect of combination treatment with leptin and cannabinoid CB1 receptor agonist on food intake and body weight gain is mediated by serotonin 1B and 2C receptors.
Wierucka-Rybak M; Wolak M; Juszczak M; Drobnik J; Bojanowska E
J Physiol Pharmacol; 2016 Jun; 67(3):457-63. PubMed ID: 27512006
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
Järbe TU; LeMay BJ; Olszewska T; Vemuri VK; Wood JT; Makriyannis A
Pharmacol Biochem Behav; 2008 Nov; 91(1):84-90. PubMed ID: 18640150
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.
Wiskerke J; Stoop N; Schetters D; Schoffelmeer AN; Pattij T
PLoS One; 2011; 6(10):e25856. PubMed ID: 22016780
[TBL] [Abstract][Full Text] [Related]
7. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
8. The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats.
Hodge J; Bow JP; Plyler KS; Vemuri VK; Wisniecki A; Salamone JD; Makriyannis A; McLaughlin PJ
Behav Brain Res; 2008 Nov; 193(2):298-305. PubMed ID: 18602425
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior.
Sink KS; Vemuri VK; Olszewska T; Makriyannis A; Salamone JD
Psychopharmacology (Berl); 2008 Mar; 196(4):565-74. PubMed ID: 18004546
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.
Kangas BD; Delatte MS; Vemuri VK; Thakur GA; Nikas SP; Subramanian KV; Shukla VG; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Mar; 344(3):561-7. PubMed ID: 23287700
[TBL] [Abstract][Full Text] [Related]
11. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.
Tallett AJ; Blundell JE; Rodgers JR
Behav Pharmacol; 2007 Nov; 18(7):591-600. PubMed ID: 17912043
[TBL] [Abstract][Full Text] [Related]
12. The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats.
McLaughlin PJ; Winston KM; Limebeer CL; Parker LA; Makriyannis A; Salamone JD
Psychopharmacology (Berl); 2005 Jul; 180(2):286-93. PubMed ID: 15948012
[TBL] [Abstract][Full Text] [Related]
13. Caffeine and cannabinoid receptors modulate impulsive behavior in an animal model of attentional deficit and hyperactivity disorder.
Leffa DT; Ferreira SG; Machado NJ; Souza CM; Rosa FD; de Carvalho C; Kincheski GC; Takahashi RN; Porciúncula LO; Souza DO; Cunha RA; Pandolfo P
Eur J Neurosci; 2019 Jun; 49(12):1673-1683. PubMed ID: 30667546
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid type 1 receptor ligands WIN 55,212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test.
Cagni P; Barros M
Behav Brain Res; 2013 Mar; 240():91-4. PubMed ID: 23183218
[TBL] [Abstract][Full Text] [Related]
15. Blockade of Serotonin 2C Receptors with SB-242084 Moderates Reduced Locomotor Activity and Rearing by Cannabinoid 1 Receptor Antagonist AM-251.
Bogáthy E; Kostyalik D; Petschner P; Vas S; Bagdy G
Pharmacology; 2019; 103(3-4):151-158. PubMed ID: 30673678
[TBL] [Abstract][Full Text] [Related]
16. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
Zhu B; Matthews JM; Xia M; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
Bioorg Med Chem Lett; 2016 Nov; 26(22):5597-5601. PubMed ID: 27671499
[TBL] [Abstract][Full Text] [Related]
17. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Järbe TU; LeMay BJ; Vemuri VK; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2011 Aug; 216(3):355-65. PubMed ID: 21369753
[TBL] [Abstract][Full Text] [Related]
18. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.
Gamage TF; Ignatowska-Jankowska BM; Wiley JL; Abdelrahman M; Trembleau L; Greig IR; Thakur GA; Tichkule R; Poklis J; Ross RA; Pertwee RG; Lichtman AH
Behav Pharmacol; 2014 Apr; 25(2):182-5. PubMed ID: 24603340
[TBL] [Abstract][Full Text] [Related]
19. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
[TBL] [Abstract][Full Text] [Related]
20. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
